Martin van Eickels

TL;DR: In participants with atrial fibrillation undergoing PCI with placement of stents, the administration of either low-dose rivaroxaban plus a P2Y12 inhibitor for 12 months or very-low-dose thrombolysis in Myocardial Infarction plus DAPT for 1, 6, or 12 months was associated with a lower rate of clinically significant bleeding.

TL;DR: In this paper, a multicenter trial was conducted to evaluate the use of dronedarone in 4628 patients with atrial fibrillation who had additional risk factors for death.

TL;DR: Dronedarone reduced the incidence of hospitalization due to cardiovascular events or death in patients with atrial fibrillation and had higher rates of bradycardia, QT-interval prolongation, nausea, diarrhea, rash and an increased serum creatinine level than the placebo group.

TL;DR: It is demonstrated that ligand bound estrogen receptor α is required for rapid activation of the IGF-1R signaling cascade.

TL;DR: Current observational worldwide data on non-valvular atrial fibrillation, collected at the end of the vitamin K antagonist-only era, indicate that these drugs are frequently not being used according to stroke risk scores and guidelines, with overuse in patients at low risk and underuse in those at high risk of stroke.